|1.||Hill, George: 3 articles (01/2012 - 08/2008)|
|2.||Klumpp, Klaus: 2 articles (05/2013 - 08/2008)|
|3.||Pockros, Paul J: 2 articles (01/2012 - 08/2008)|
|4.||Chan, Anna: 2 articles (01/2012 - 08/2008)|
|5.||Najera, Isabel: 2 articles (08/2008 - 08/2008)|
|6.||Fink, Katja: 1 article (02/2014)|
|7.||Cerny, Daniela: 1 article (02/2014)|
|8.||Chen, Yen-Liang: 1 article (02/2014)|
|9.||Abdul Ghafar, Nahdiyah: 1 article (02/2014)|
|10.||Herve, Maxime: 1 article (02/2014)|
|1.||Chronic Hepatitis C
01/01/2012 - "Further development of balapiravir for the treatment of chronic hepatitis C has been halted because of the unacceptable benefit to risk ratio revealed in this study (www.ClinicalTrials.gov NCT 00517439)."
08/01/2008 - "A multicenter, observer-blinded, randomized, placebo-controlled, multiple ascending dose, phase 1b study was designed to evaluate the safety, pharmacokinetics, and antiviral activity and to potentially identify the maximum tolerated dose of R1626 in patients with chronic hepatitis C. "
08/01/2008 - "Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C."
10/01/2008 - "R-1626 was generally well tolerated, although severe side effects of neutropenia were observed at high doses. "
01/01/2012 - "Serious hematological adverse events (particularly neutropenia, lymphopenia) were more common in balapiravir recipients. "
08/01/2008 - "A synergistic antiviral effect was observed when R1626 was combined with peginterferon alfa-2a +/- ribavirin; up to 74% of patients had undetectable HCV RNA at week 4. Dosing of R1626 was limited by neutropenia; a study of different dosages of R1626 in combination with peginterferon alfa-2a and ribavirin is underway."
02/01/2014 - "Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir."
10/01/2008 - "Given its potent antiviral effect with an apparent high genetic barrier, R-1626 represents an important advancement in improving the outcome of patients with chronic HCV infection."
08/01/2008 - "These data support further studies of R1626 in combination with peginterferon alfa-2a and ribavirin for the treatment of patients with chronic HCV infection."
10/01/2008 - "After 4 weeks of treatment with R-1626 in combination with PEG-IFN plus ribavirin in treatment-naïve patients with genotype 1 HCV infection, HCV RNA could no longer be detected in approximately 74% of patients, compared with 5% of patients treated with PEG-IFN plus ribavirin alone, indicating the high potency of R-1626 to induce HCV RNA viral load reductions. "
|4.||Dengue (Dengue Fever)
05/01/2013 - "Although this trial, the first of its kind in dengue, does not support balapiravir as a candidate drug, it does establish a framework for antiviral treatment trials in dengue and provides the field with a clinically evaluated benchmark molecule. "
05/01/2013 - "A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients."
05/01/2013 - "We conducted in vitro experiments to determine the potency of balapiravir against dengue viruses and then an exploratory, dose-escalating, randomized placebo-controlled trial in adult male patients with dengue with <48 hours of fever. "
02/01/2014 - "The elevated EC(50) was greater than the plasma trough concentration of R1479 observed in dengue patients treated with balapiravir and could possibly explain the efficacy failure. "
02/01/2014 - "In a recent clinical trial, balapiravir, a prodrug of a cytidine analog (R1479), failed to achieve efficacy (reducing viremia after treatment) in dengue patients, although the plasma trough concentration of R1479 remained above the 50% effective concentration (EC(50)). "
|2.||peginterferon alfa-2a (Pegasys)
|3.||RNA (Ribonucleic Acid)